Scotiabank Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $13
Scotiabank Keeps Their Buy Rating on Tempest Therapeutics (TPST)
Tempest Therapeutics Analyst Ratings
Buy Rating Affirmed for Tempest Therapeutics Amidst Promising Phase 3 Outlook and Funding Uncertainties
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Buy Rating Affirmed for Tempest Therapeutics Amid Strong Clinical Results and Solid Financials
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), CVS Health (CVS) and Tempest Therapeutics (TPST)
Tempest Therapeutics Analyst Ratings
Tempest Therapeutics Analyst Ratings
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Buy Rating Affirmed for Tempest Therapeutics Amidst Promising Clinical Advancements
Tempest Therapeutics (TPST) Receives a Buy From Scotiabank
Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)
Tempest Therapeutics Analyst Ratings
Tempest Therapeutics Analyst Ratings
Buy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial Prospects
Tempest Therapeutics Analyst Ratings
Tempest Therapeutics Analyst Ratings
Growth Potential and Strategic Partnerships: Reasons for Aydin Huseynov's Buy Rating on Tempest Therapeutics
Piper Sandler Sticks to Their Buy Rating for Tempest Therapeutics (TPST)